论文部分内容阅读
目的观察人尿激肽原酶(尤瑞克林)对老年急性脑梗死患者的临床疗效。方法选取62例急性脑梗死患者,年龄介于60～75岁之间,随机分为两组。对照组给予一般常规治疗,治疗组在常规治疗基础上给予尤瑞克林0.15PNA单位静脉滴注,1次/d,两组疗程均为14d,分别于治疗前后采用美国国立卫生院卒中量表(NIHSS)评价患者神经功能缺损的变化情况。并在治疗后90d随访时用改良Rankin量表(mRS)评定患者临床预后及独立生活能力。结果尤瑞克林组临床有效率为84.4%,对照组为60.0%,两组比较,差异有统计学意义;据mRS评分评估患者预后,尤瑞克林组预后良好比率亦高于对照组。结论人尿激肽原酶能有效的改善老年急性脑梗死患者的神经功能缺损及临床预后。
Objective To observe the clinical efficacy of human urokinase (urelin) in senile patients with acute cerebral infarction. Methods Sixty-two patients with acute cerebral infarction were selected, aged from 60 to 75 years old and were randomly divided into two groups. The control group was given conventional treatment. The treatment group received intravenous drip of 0.15PNA of uracil once a day for 14 days. The treatment groups were treated with the National Institutes of Health Stroke Scale (NIHSS) evaluation of patients with neurological deficit changes. And 90d follow-up after treatment with modified Rankin scale (mRS) to assess the clinical prognosis and independent living ability. Results The clinical effective rate was 84.4% in uric chloride group and 60.0% in control group. There was significant difference between the two groups. The mRS score was also used to evaluate the prognosis of patients. The good rate of prognosis in uriclin group was also higher than that in control group. Conclusions Human kallikrein can effectively improve neurological deficits and clinical prognosis in elderly patients with acute cerebral infarction.